Benzothiazole and benzimidazole derivatives, pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition comprising same as active ingredient
AssigneeKorea Research Institute of Chemical Technology
InventorsKwang Rok KIM, Kwan Young JEONG, Hee Jung JUNG, Doyoun KIM, Junmi LEE, Sang Dal RHEE, Kyu Myung LEE
Life of this patent
Estimating the term…
Abstract
The present invention relates to a benzothiazole or benzimidazole derivative, a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same as an active ingredient for prevention or treatment of SIRTUIN 7 protein-related diseases. With excellent inhibitory activity against SIRTUIN 7 protein the derivative can be used for preventing or treating SIRTUIN 7 protein-related diseases.
Claims10
A compound represented by Formula 1, a stereoisomer, tautomer, derivative, hydrate, solvate or pharmaceutically acceptable salt thereof:
- Wherein:
- 1) X is S or N(R1),
- 2) wherein R1 is hydrogen;
- C1˜C5 alkyl group;
- or a C7˜C20 arylalkyl group substituted with fluorine;
- 3) Y is independently of each other N or CH,
- 4) R2 are each the same or different, and each independently hydrogen;
- or halogen;
- 5) L is a single bond;
- C1˜C6 alkylene group;
- C2˜C6 alkenylene group;
- a substituent represented by Formula 2-1;
- or a substituent represented by Formula 2-2;
- 6) L′ is selected from a group consisting of a single bond;
- C1˜C10 alkylene group;
- C2˜C10 alkenylene group;
- and —(CnH2n)—O—(CnH2n)—;
- 7) * represents a position bonded to L, * 1 represents a position bonded to Ar,
- 8) R3 are each the same or different, and is each independently selected from the group consisting of hydrogen;
- halogen;
- and a C1˜C10 alkyl group unsubstituted or substituted with fluorine,
- 9) Ar is a C6˜C20 arylene group;
- or a C2˜C20 heterocyclic group comprising at least one heteroatom of N and O;
- 10) R1 is selected from the group consisting of hydrogen;
- halogen;
- a C1˜C10 alkyl group unsubstituted or substituted with fluorine;
- —SO2—Ra;
- —CO—NH—Rb;
- and —CO—Rc;
- 11) wherein Ra is selected from the group consisting of a C1˜C10 alkyl group;
- C3˜C20 aliphatic ring group;
- C6˜C20 aryl group unsubstituted or substituted with CF3;
- and —N(R′)(R″);
- 12) wherein R′ and R″ are each independently a C1˜C10 alkyl group;
- 13) wherein Rb is selected from the group consisting of a C6˜C20 aryl group;
- C3˜C20 aliphatic ring group;
- fused ring group of C3˜C20 aliphatic ring and C6˜C20 aromatic ring;
- a C1˜C20 alkyl group unsubstituted or substituted with halogen;
- and —(CmH2m)—CO—O—(CmH2m+1);
- 14) Wherein Rc is selected from the group consisting of a C1˜C10 alkyl group;
- C6˜C20 aryl group;
- and C1˜C10 alkoxy group;
- 15) a is 0 or 1, b is an integer from 0 to 3, c is an integer from 0 to 4, n is independently an integer from 0 to 2, m is independently an integer from 1 to 6,
- 16) wherein, the alkyl group, the alkenyl group, the alkoxy group, the aryl group, the arylalkyl group, the alkylene group, the alkenylene group, the arylene group, the aliphatic ring group, the heterocyclic group, and the fused ring group may be further substituted with one or more substituents selected from the group consisting of halogen;
- C1˜C10 alkyl group;
- C2˜C10 alkenyl group;
- C2˜C10 alkynyl group;
- C1˜C10 alkoxy group;
- C1˜C10 carbonyl group;
- and a C1˜C10 alkyl group substituted with fluorine.
Dependencies are inferred from the claim text.